Does the media refer more to EWTX or SPRY?

In the previous week, Edgewise Therapeutics and Edgewise Therapeutics both had 3 articles in the media. ARS Pharmaceuticals' average media sentiment score of 1.47 beat Edgewise Therapeutics' score of 0.08 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SPRY or CRNX?

In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for Crinetics Pharmaceuticals and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.47 beat Crinetics Pharmaceuticals' score of 0.57 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Crinetics Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer SPRY or ACAD?

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.47 beat ACADIA Pharmaceuticals' score of 0.56 indicating that ARS Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ARS Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ACADIA Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

ARS Pharmaceuticals (SPRY) Competitors

$10.28 +0.30 (+3.01%)

Closing price 04:00 PM Eastern

Extended Trading

$10.27 -0.01 (-0.14%)

As of 07:59 PM Eastern

Compare

SPRY vs. CPRX, EWTX, CRNX, ACAD, and NAMS

Should you buy ARS Pharmaceuticals stock or one of its competitors? MarketBeat compares ARS Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ARS Pharmaceuticals include Catalyst Pharmaceuticals (CPRX), Edgewise Therapeutics (EWTX), Crinetics Pharmaceuticals (CRNX), ACADIA Pharmaceuticals (ACAD), and NewAmsterdam Pharma (NAMS). These companies are all part of the "pharmaceutical products" industry.

How does ARS Pharmaceuticals compare to Catalyst Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Catalyst Pharmaceuticals (NASDAQ:CPRX) are both medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, valuation, analyst recommendations, media sentiment, dividends, risk, institutional ownership and earnings.

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than Catalyst Pharmaceuticals. MarketBeat recorded 3 mentions for ARS Pharmaceuticals and 0 mentions for Catalyst Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.47 beat Catalyst Pharmaceuticals' score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
ARS Pharmaceuticals	Positive
Catalyst Pharmaceuticals	Neutral

Catalyst Pharmaceuticals has a net margin of 37.08% compared to ARS Pharmaceuticals' net margin of -200.00%. Catalyst Pharmaceuticals' return on equity of 35.76% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Catalyst Pharmaceuticals	37.08%	35.76%	31.31%

Catalyst Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than Catalyst Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	12.11	-$171.30M	-$2.01	N/A
Catalyst Pharmaceuticals	$588.99M	6.53	$214.33M	$1.74	18.05

ARS Pharmaceuticals presently has a consensus price target of $28.60, indicating a potential upside of 178.21%. Catalyst Pharmaceuticals has a consensus price target of $32.00, indicating a potential upside of 1.91%. Given ARS Pharmaceuticals' higher probable upside, equities research analysts clearly believe ARS Pharmaceuticals is more favorable than Catalyst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Catalyst Pharmaceuticals	0 Sell rating(s)	6 Hold rating(s)	1 Buy rating(s)	2 Strong Buy rating(s)	2.56

68.2% of ARS Pharmaceuticals shares are held by institutional investors. Comparatively, 79.2% of Catalyst Pharmaceuticals shares are held by institutional investors. 33.8% of ARS Pharmaceuticals shares are held by insiders. Comparatively, 10.4% of Catalyst Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

ARS Pharmaceuticals has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, Catalyst Pharmaceuticals has a beta of 0.74, meaning that its stock price is 26% less volatile than the broader market.

Summary

Catalyst Pharmaceuticals beats ARS Pharmaceuticals on 10 of the 17 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Edgewise Therapeutics?

Edgewise Therapeutics (NASDAQ:EWTX) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, media sentiment, risk, valuation, profitability, analyst recommendations, institutional ownership and dividends.

Edgewise Therapeutics has a beta of 0.27, indicating that its stock price is 73% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, indicating that its stock price is 6% less volatile than the broader market.

Edgewise Therapeutics has a net margin of 0.00% compared to ARS Pharmaceuticals' net margin of -200.00%. Edgewise Therapeutics' return on equity of -32.55% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Edgewise Therapeutics	N/A	-32.55%	-31.04%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

Edgewise Therapeutics has higher earnings, but lower revenue than ARS Pharmaceuticals. Edgewise Therapeutics is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Edgewise Therapeutics	N/A	N/A	-$167.79M	-$1.66	N/A
ARS Pharmaceuticals	$84.28M	12.11	-$171.30M	-$2.01	N/A

Edgewise Therapeutics presently has a consensus target price of $47.30, indicating a potential upside of 21.81%. ARS Pharmaceuticals has a consensus target price of $28.60, indicating a potential upside of 178.21%. Given ARS Pharmaceuticals' higher probable upside, analysts clearly believe ARS Pharmaceuticals is more favorable than Edgewise Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Edgewise Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.78
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. 21.3% of Edgewise Therapeutics shares are owned by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

In the previous week, Edgewise Therapeutics and Edgewise Therapeutics both had 3 articles in the media. ARS Pharmaceuticals' average media sentiment score of 1.47 beat Edgewise Therapeutics' score of 0.08 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Edgewise Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Edgewise Therapeutics beats ARS Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to Crinetics Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their earnings, valuation, risk, institutional ownership, dividends, profitability, media sentiment and analyst recommendations.

ARS Pharmaceuticals has a net margin of -200.00% compared to Crinetics Pharmaceuticals' net margin of -2,747.18%. Crinetics Pharmaceuticals' return on equity of -43.96% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
Crinetics Pharmaceuticals	-2,747.18%	-43.96%	-39.61%

ARS Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

ARS Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Crinetics Pharmaceuticals is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	12.11	-$171.30M	-$2.01	N/A
Crinetics Pharmaceuticals	$7.70M	491.73	-$465.32M	-$5.13	N/A

ARS Pharmaceuticals presently has a consensus price target of $28.60, suggesting a potential upside of 178.21%. Crinetics Pharmaceuticals has a consensus price target of $76.13, suggesting a potential upside of 111.99%. Given ARS Pharmaceuticals' higher possible upside, analysts plainly believe ARS Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
Crinetics Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.90

In the previous week, Crinetics Pharmaceuticals had 3 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 6 mentions for Crinetics Pharmaceuticals and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.47 beat Crinetics Pharmaceuticals' score of 0.57 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Crinetics Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

ARS Pharmaceuticals beats Crinetics Pharmaceuticals on 9 of the 17 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to ACADIA Pharmaceuticals?

ARS Pharmaceuticals (NASDAQ:SPRY) and ACADIA Pharmaceuticals (NASDAQ:ACAD) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, media sentiment, earnings, risk and valuation.

ACADIA Pharmaceuticals has a net margin of 34.30% compared to ARS Pharmaceuticals' net margin of -200.00%. ACADIA Pharmaceuticals' return on equity of 9.61% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%
ACADIA Pharmaceuticals	34.30%	9.61%	7.07%

68.2% of ARS Pharmaceuticals shares are owned by institutional investors. Comparatively, 96.7% of ACADIA Pharmaceuticals shares are owned by institutional investors. 33.8% of ARS Pharmaceuticals shares are owned by company insiders. Comparatively, 26.2% of ACADIA Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

ACADIA Pharmaceuticals has higher revenue and earnings than ARS Pharmaceuticals. ARS Pharmaceuticals is trading at a lower price-to-earnings ratio than ACADIA Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ARS Pharmaceuticals	$84.28M	12.11	-$171.30M	-$2.01	N/A
ACADIA Pharmaceuticals	$1.07B	3.61	$391M	$2.20	10.27

In the previous week, ACADIA Pharmaceuticals had 1 more articles in the media than ARS Pharmaceuticals. MarketBeat recorded 4 mentions for ACADIA Pharmaceuticals and 3 mentions for ARS Pharmaceuticals. ARS Pharmaceuticals' average media sentiment score of 1.47 beat ACADIA Pharmaceuticals' score of 0.56 indicating that ARS Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ARS Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ACADIA Pharmaceuticals	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ARS Pharmaceuticals currently has a consensus target price of $28.60, indicating a potential upside of 178.21%. ACADIA Pharmaceuticals has a consensus target price of $31.63, indicating a potential upside of 39.93%. Given ARS Pharmaceuticals' higher probable upside, analysts plainly believe ARS Pharmaceuticals is more favorable than ACADIA Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50
ACADIA Pharmaceuticals	1 Sell rating(s)	3 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.67

ARS Pharmaceuticals has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market. Comparatively, ACADIA Pharmaceuticals has a beta of 0.83, suggesting that its share price is 17% less volatile than the broader market.

Summary

ACADIA Pharmaceuticals beats ARS Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does ARS Pharmaceuticals compare to NewAmsterdam Pharma?

NewAmsterdam Pharma (NASDAQ:NAMS) and ARS Pharmaceuticals (NASDAQ:SPRY) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

ARS Pharmaceuticals has higher revenue and earnings than NewAmsterdam Pharma. NewAmsterdam Pharma is trading at a lower price-to-earnings ratio than ARS Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NewAmsterdam Pharma	$22.50M	163.14	-$203.82M	-$1.79	N/A
ARS Pharmaceuticals	$84.28M	12.11	-$171.30M	-$2.01	N/A

NewAmsterdam Pharma presently has a consensus target price of $48.60, suggesting a potential upside of 54.78%. ARS Pharmaceuticals has a consensus target price of $28.60, suggesting a potential upside of 178.21%. Given ARS Pharmaceuticals' higher possible upside, analysts clearly believe ARS Pharmaceuticals is more favorable than NewAmsterdam Pharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NewAmsterdam Pharma	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83
ARS Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.50

In the previous week, ARS Pharmaceuticals had 3 more articles in the media than NewAmsterdam Pharma. MarketBeat recorded 3 mentions for ARS Pharmaceuticals and 0 mentions for NewAmsterdam Pharma. ARS Pharmaceuticals' average media sentiment score of 1.47 beat NewAmsterdam Pharma's score of 0.00 indicating that ARS Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
NewAmsterdam Pharma	Neutral
ARS Pharmaceuticals	Positive

NewAmsterdam Pharma has a beta of 0.07, suggesting that its stock price is 93% less volatile than the broader market. Comparatively, ARS Pharmaceuticals has a beta of 0.94, suggesting that its stock price is 6% less volatile than the broader market.

ARS Pharmaceuticals has a net margin of -200.00% compared to NewAmsterdam Pharma's net margin of -943.23%. NewAmsterdam Pharma's return on equity of -26.49% beat ARS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NewAmsterdam Pharma	-943.23%	-26.49%	-24.37%
ARS Pharmaceuticals	-200.00%	-153.61%	-60.85%

89.9% of NewAmsterdam Pharma shares are held by institutional investors. Comparatively, 68.2% of ARS Pharmaceuticals shares are held by institutional investors. 12.7% of NewAmsterdam Pharma shares are held by insiders. Comparatively, 33.8% of ARS Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

ARS Pharmaceuticals beats NewAmsterdam Pharma on 9 of the 17 factors compared between the two stocks.

Get ARS Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SPRY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SPRY vs. The Competition

Export

Metric	ARS Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$991.05M	$2.97B	$6.45B	$12.39B
Dividend Yield	N/A	1.80%	2.69%	5.83%
P/E Ratio	-5.11	18.43	24.92	23.97
Price / Sales	12.11	336.82	528.81	109.59
Price / Cash	N/A	56.31	44.82	54.51
Price / Book	8.86	4.11	10.79	6.50
Net Income	-$171.30M	$64.45M	$3.56B	$336.88M
7 Day Performance	5.98%	2.24%	1.67%	-0.22%
1 Month Performance	29.47%	1.04%	0.43%	0.77%
1 Year Performance	-37.96%	30.05%	32.84%	31.57%

ARS Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SPRY ARS Pharmaceuticals	2.9677 of 5 stars	$10.28 +3.0%	$28.60 +178.2%	-36.8%	$991.05M	$84.28M	N/A	90	News Coverage
CPRX Catalyst Pharmaceuticals	2.8876 of 5 stars	$31.37 +0.0%	$32.00 +2.0%	+39.6%	$3.84B	$588.99M	18.03	80	Positive News
EWTX Edgewise Therapeutics	2.2488 of 5 stars	$35.21 +1.1%	$44.22 +25.6%	+155.2%	$3.75B	N/A	N/A	60
CRNX Crinetics Pharmaceuticals	3.1979 of 5 stars	$35.12 +1.9%	$76.13 +116.8%	+17.3%	$3.63B	$7.70M	N/A	210
ACAD ACADIA Pharmaceuticals	4.0871 of 5 stars	$21.26 +0.8%	$31.63 +48.8%	-2.7%	$3.61B	$1.07B	9.66	510	News Coverage

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SPRY) was last updated on 6/23/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. CPRX, EWTX, CRNX, ACAD, and NAMS

How does ARS Pharmaceuticals compare to Catalyst Pharmaceuticals?

Summary

How does ARS Pharmaceuticals compare to Edgewise Therapeutics?

Summary

How does ARS Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does ARS Pharmaceuticals compare to ACADIA Pharmaceuticals?

Summary

How does ARS Pharmaceuticals compare to NewAmsterdam Pharma?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ARS Pharmaceuticals (SPRY) Competitors

SPRY vs. CPRX, EWTX, CRNX, ACAD, and NAMS

How does ARS Pharmaceuticals compare to Catalyst Pharmaceuticals?

Does the media refer more to SPRY or CPRX?

Is SPRY or CPRX more profitable?

Which has better earnings & valuation, SPRY or CPRX?

Do analysts rate SPRY or CPRX?

Do institutionals & insiders believe in SPRY or CPRX?

Which has more volatility & risk, SPRY or CPRX?

Summary

How does ARS Pharmaceuticals compare to Edgewise Therapeutics?

Which has more risk & volatility, EWTX or SPRY?

Is EWTX or SPRY more profitable?

Which has stronger valuation and earnings, EWTX or SPRY?

Do analysts rate EWTX or SPRY?

Do institutionals & insiders believe in EWTX or SPRY?

Does the media refer more to EWTX or SPRY?

Summary

How does ARS Pharmaceuticals compare to Crinetics Pharmaceuticals?

Is SPRY or CRNX more profitable?

Which has more volatility & risk, SPRY or CRNX?

Do insiders & institutionals have more ownership in SPRY or CRNX?

Which has better valuation & earnings, SPRY or CRNX?

Do analysts recommend SPRY or CRNX?

Does the media prefer SPRY or CRNX?

Summary

How does ARS Pharmaceuticals compare to ACADIA Pharmaceuticals?

Is SPRY or ACAD more profitable?

Do institutionals and insiders believe in SPRY or ACAD?

Which has stronger earnings & valuation, SPRY or ACAD?

Does the media prefer SPRY or ACAD?

Do analysts prefer SPRY or ACAD?

Which has more volatility & risk, SPRY or ACAD?

Summary

How does ARS Pharmaceuticals compare to NewAmsterdam Pharma?

Which has preferable earnings & valuation, NAMS or SPRY?

Do analysts recommend NAMS or SPRY?

Does the media favor NAMS or SPRY?

Which has more volatility & risk, NAMS or SPRY?

Is NAMS or SPRY more profitable?

Do insiders and institutionals believe in NAMS or SPRY?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRY vs. The Competition

ARS Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools